Target Engagement of Terazosin in Healthy Adults

Phase 1Active Not RecruitingNCT04551040

University of Iowa18 enrolled

Overview

The purpose of the study is to assess the target engagement of Terazosin (TZ) in a single cohort of 6 healthy adult participants. During the study participants will undergo PET/CT scans, 7-Tesla MRI scans, blood draws, and an optional lumbar puncture (LP.)

The study is a single center, 37-day, controlled pilot study to assess the target engagement of Terazosin (TZ) in a single cohort of 6 healthy adult participants (3 men and 3 women.) During the study participants will undergo PET/CT scans, 7-Tesla MRI scans, blood draws, and an optional lumbar puncture (LP.) Participants will have their baseline ATP levels measured (at 0mg TZ.) They will then take doses of TZ at 1mg and will increase their dose on a weekly basis by 1mg until they reach a total dose of 5mg. ATP levels will be assessed on study days 8 and 36. Participants interested in voluntarily donating a sample of cerebral spinal fluid will undergo an optional lumbar puncture on study day 37. The purpose of the study is to gain a better understanding of the mechanisms in which TZ acts in the brain. TZ was recently discovered to increase energy levels (in the form of ATP molecules) in the brain by enhancing glycolysis. By using different brain imaging techniques, blood assays and cerebral spinal fluid assays, the study will attempt to: 1) quantify the rate of glycolysis in the brain at different dosages of TZ, 2) quantify ATP levels in the brain at different dosages of TZ, 3) quantify ATP levels in blood at different dosages of TZ, and 4) assess the brain permeability of TZ. It is hoped that knowledge gained from the study will help guide future clinical trials using TZ for the treatment of various neurodegenerative diseases such as Parkinson's Disease.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

TerazosinDRUG

Terazosin 1 mg oral capsule

Eligibility

Sex: ALLMin age: 60 YearsMax age: 90 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy Men or women aged 60-90 Exclusion Criteria: * History of stroke * Ineligibility for MRI (e.g. soft tissue metallic implants, clips, cardiac pacemaker, cardiac defibrillator, internal pacing wires, metallic fragments, shrapnel, etc.) * Current use of more than one of the following classes of medications: beta blockers, ace inhibitors, angiotensin receptor blockers, calcium channel blockers, or diuretics * Use of any alpha blockers (terazosin, doxazosin, alfuzosin, prazosin, or tamsulosin) in the past year. * Current use of the over-the-counter supplement yohimbe * Orthostatic hypotension defined as symptomatic decrease in BP \> 20mmHg systolic or \> 10mmHg diastolic and HR increase \< 20bpm on supine to sitting or standing. * Alcohol and drug abuse * Clinically significant traumatic brain injury * History of Type I diabetes * Uncontrolled Type II diabetes * Other known medical or psychiatric comorbidity that in the investigator's opinion would compromise participation in the study or increase fall risk * Use of investigational drugs within 30 days before screening * History of hemodynamic instability * For females: pregnancy or breastfeeding

Locations (1)

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States

Outcomes

Primary Outcomes

Quantification of glycolysis in the brain at baseline

Use of FDG PET to quantify glycolysis in the brain at baseline prior to initiation of terazosin

Time frame: Study day 1

Change in glycolysis in the brain from baseline to 1 week (1mg of terazosin)

Use of FDG PET to determine how TZ quantitatively increases glycolysis as measured by FDG uptake from baseline to 1 week (Day 8/ 1mg TZ)

Time frame: Study day 8

Change in glycolysis in the brain from baseline to 5 weeks (5mg of terazosin)

Use of FDG PET to determine how TZ quantitatively increases glycolysis as measured by FDG uptake from baseline to 5 weeks (Day 36/ 5mg TZ)

Time frame: Study day 36

Quantification of ATP in brain at baseline

Use of Magnetic Resonance Spectroscopy (MRS) to quantify ATP in the brain at baseline prior to initiation of terazosin

Time frame: Study day 1

Change in ATP in the brain from baseline to 1 week (1mg of terazosin)

Use of Magnetic Resonance Spectroscopy (MRS) determine how TZ quantitatively increases ATP as measured by MRS from baseline to 1 week (Day 8/ 1mg TZ)

Time frame: Study day 8

Change in ATP in the brain from baseline to 5 weeks (5mg of terazosin)

Use of Magnetic Resonance Spectroscopy (MRS) determine how TZ quantitatively increases ATP as measured by MRS from baseline to 5 weeks (Day 36/ 5mg TZ)

Time frame: Study day 36

Quantification of ATP in blood at baseline

Use of a novel assay to quantify ATP in the blood at baseline prior to initiation of terazosin

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.